Unlocking hope: HCV re-treatment strategy for patients with active hepatocellular carcinoma.
作者信息
Shah Sital, Guerra Veloz Maria Fernanda, Agarwal Kosh, Cannon Mary
机构信息
Institute of Liver Studies, King's College Hospital, Denmark Hill, London, SE5 9RS, UK.
Pharmacy Department, Kings College Hospital, Denmark Hill, London, SE5 9RS, UK.
出版信息
JHEP Rep. 2024 Apr 7;6(11):101093. doi: 10.1016/j.jhepr.2024.101093. eCollection 2024 Nov.
Abstract
摘要
相似文献
1
Unlocking hope: HCV re-treatment strategy for patients with active hepatocellular carcinoma.开启希望：针对活动性肝细胞癌患者的丙型肝炎病毒再治疗策略
JHEP Rep. 2024 Apr 7;6(11):101093. doi: 10.1016/j.jhepr.2024.101093. eCollection 2024 Nov.
2
HCV-hepatocellular carcinoma: new findings and hope for effective treatment.丙型肝炎病毒相关性肝细胞癌：新发现与有效治疗的希望
Microsc Res Tech. 2005 Nov;68(3-4):130-48. doi: 10.1002/jemt.20227.
3
Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma.直接作用抗病毒治疗在伴有代偿期肝硬化和肝细胞癌的丙型肝炎感染肝移植候选者中的成本效益
Transplantation. 2017 May;101(5):1001-1008. doi: 10.1097/TP.0000000000001605.
4
Long interval between HCV infection and development of hepatocellular carcinoma.
Liver. 1995 Jun;15(3):159-63. doi: 10.1111/j.1600-0676.1995.tb00664.x.
5
Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels.低丙型肝炎病毒核糖核酸水平的肝细胞癌患者的干扰素治疗
Hepatogastroenterology. 2002 May-Jun;49(45):724-9.
6
High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis.丙型肝炎病毒（HCV）NS5A内的高氨基酸变异性与HCV-1b相关肝硬化患者的肝细胞癌有关。
Hepatology. 2001 Jul;34(1):158-67. doi: 10.1053/jhep.2001.25512.
7
8
Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.肝细胞癌会降低使用直接作用抗病毒药物成功治疗丙型肝炎病毒的几率。
J Hepatol. 2017 Jun;66(6):1173-1181. doi: 10.1016/j.jhep.2017.01.020. Epub 2017 Feb 2.
9
Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication.丙型肝炎病毒治愈率在活动性而非静止性肝细胞癌患者中降低：一个实践意义。
Clin Infect Dis. 2020 Dec 31;71(11):2840-2848. doi: 10.1093/cid/ciz1160.
10
Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United States.美国黑人和白人肝细胞癌患者中乙型和丙型肝炎病毒标志物的流行情况。
J Natl Cancer Inst. 1990 Jun 20;82(12):1038-41. doi: 10.1093/jnci/82.12.1038.
本文引用的文献
1
Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure.伏西拉普瑞韦/维帕他韦/索磷布韦在直接抗病毒药物治疗失败患者中的真实世界有效性
JHEP Rep. 2024 Feb 7;6(3):100994. doi: 10.1016/j.jhepr.2023.100994. eCollection 2024 Mar.
2
Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.《2023年丙型肝炎指南更新：美国肝病研究学会-美国感染病学会关于丙型肝炎病毒感染检测、管理及治疗的建议》
Clin Infect Dis. 2023 May 25. doi: 10.1093/cid/ciad319.
3
Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients.索磷布韦、格卡瑞韦、哌仑他韦和利巴韦林作为难治性丙型肝炎患者的挽救疗法
Hepatology. 2021 Oct;74(4):2304-2306. doi: 10.1002/hep.31909. Epub 2021 Jun 16.
4
Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis.直接作用抗病毒药物治疗丙型肝炎病毒后肝细胞癌复发：一项系统评价与荟萃分析
J Clin Med. 2021 Apr 15;10(8):1694. doi: 10.3390/jcm10081694.
5
Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection.接受glecaprevir/pibrentasvir治疗丙型肝炎病毒感染失败患者的再治疗。
J Hepatol. 2019 May;70(5):1019-1023. doi: 10.1016/j.jhep.2019.01.031. Epub 2019 Mar 8.
6
EASL Recommendations on Treatment of Hepatitis C 2018.2018年欧洲肝脏研究学会丙型肝炎治疗推荐意见
J Hepatol. 2018 Aug;69(2):461-511. doi: 10.1016/j.jhep.2018.03.026. Epub 2018 Apr 9.
Zotero 插件